Albireo Pharma (NASDAQ:ALBO) reported topline results from its Phase 2 trial evaluating elobixibat for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
The trial enrolled 47 patients who received a once daily 5 mg dose of elobixibat, or placebo, for 16 weeks. The study met its primary endpoint of change from baseline in serum low-density lipoprotein cholesterol, but did not achieve proof-of-concept for other key NASH measures.
“We wanted to investigate the potential of elobixibat in NASH and allocated minimal resources to an exploratory Phase 2 study,” Ron Cooper, Albireo’s president and CEO, said in a statement.
“Based on the results of this study, we have made the decision not to pursue further development of elobixibat in NASH. Our main focus continues to be on odevixibat in rare pediatric liver diseases and we look forward to our Phase 3 topline data in the coming weeks,” he added.
